Who Paid My Doc
Jeffrey Call
Internal Medicine Ogden, UT Medical Doctor
NPI 1093747743 CMS profile 4595
4403 Harrison Blvd, Ste 3875, Ogden, UT 84403
General payments
$44
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Jeffrey Call of Ogden, UT is reported in the CMS Open Payments database as having received $44 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 17th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $44 | 1 |
Beside peers
- Jeffrey Call
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to Jeffrey Call were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | Jeffrey Call | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $159 | $48–$570 | $163 |
| 2020 | $0 | $119 | $33–$402 | $114 |
| 2021 | $0 | $135 | $37–$521 | $132 |
| 2022 | $44 | $141 | $42–$496 | $149 |
| 2023 | $0 | $149 | $45–$519 | $160 |
| 2024 | $0 | $154 | $47–$537 | $164 |
| 2025 | $0 | $156 | $47–$551 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 176 drugsPart D claims
12,555
Drug cost
$912,794
Branded share of claims
18%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | Brand | 157 | $175,102 | |
| Jardiance Empagliflozin | Brand | 152 | $139,440 | |
| Eliquis Apixaban | Brand | 168 | $125,773 | |
| Xarelto Rivaroxaban | Brand | 55 | $60,338 | |
| Ozempic Semaglutide | Brand | 43 | $41,468 | |
| Trulicity Dulaglutide | Brand | 39 | $39,153 | |
| Januvia Sitagliptin Phosphate | Brand | 34 | $33,671 | |
| Myrbetriq Mirabegron | Brand | 18 | $20,979 | |
| Farxiga Dapagliflozin Propanediol | Brand | 30 | $20,939 | |
| Livalo Pitavastatin Calcium | Brand | 12 | $10,383 |
The 10 drugs with the highest cost, of 176 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 48 billing codesPaid by Medicare
$214,012
Medicare patients
405
Services billed
10,724
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 74% | |
| Arthritis | 44% | |
| Chronic kidney disease | 42% | |
| Ischemic heart disease | 30% | |
| Depression | 30% | |
| Diabetes | 26% | |
| Osteoporosis | 22% | |
| Heart failure | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, denosumab, 1 mg J0897 | Office | 27 | 2,520 | $51,085 |
| Sarscv2 vac 30mcg trs-suc im 91320 | Office | 102 | 107 | $15,983 |
| Vaccine for influenza for injection into muscle 90662 | Office | 121 | 121 | $9,900 |
| Pcv20 vaccine im 90677 | Office | 29 | 29 | $7,162 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 12 | 60 | $236 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 17 | 46 | $40 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in Utah
Willard Dere
Internal Medicine · Salt Lake City, UT
Kenneth Schaecher
Internal Medicine · West Valley City, UT
Steven Call
Internal Medicine · Springville, UT
James Chamberlain
Internal Medicine · Salt Lake City, UT
Alexander Pastuszak
Internal Medicine · Salt Lake City, UT
Zameer Abedin
Internal Medicine · Salt Lake City, UT
Related records
Internal Medicine in Utah
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Utah
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.